February 24, 2023Open Access

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors

Key Points

Key points are not available for this paper at this time.

Abstract

Patients with NSCLC with poor ECOG PS treated with ICI had significantly worse survival outcomes and were significantly more likely to use health care services than those with favorable ECOG PS. The large proportion of patients with poor ECOG PS further justifies the urgent need for randomized trials evaluating the efficacy of ICI in this high-risk population.

AIに質問

Bookmark

View Full Paper

Cite This Study

Meyers et al. (Fri,) studied this question.

synapsesocial.com/papers/69d8f1371ab91f1400bed9e2 https://doi.org/https://doi.org/10.1016/j.jtocrr.2023.100482

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology2021 · 43 citations
2Association of Early Palliative Care Use With Survival and Place of Death Among Patients With Advanced Lung Cancer Receiving Care in the Veterans Health Administration2019 · 172 citations
3Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)2019 · 187 citations
4Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer2021 · 662 citations
5Time-Related Burdens of Cancer Care2021 · 54 citations

AIに質問

Bookmark

View Full Paper